Catja Freiburghaus (Former)
1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
(
- Contribution to journal › Article
- 2019
-
Mark
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
(
- Contribution to journal › Article
- 2018
-
Mark
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
(
- Contribution to journal › Article
- 2012
-
Mark
Reduction of ultraviolet light-induced DNA damage in human colon cancer cells treated with a lactoferrin-derived peptide
(
- Contribution to journal › Article
- 2010
-
Mark
Health Promoting Effects of Bioactive Peptides in Milk - Studies on Cultured Normal Cells and Cancer Cells
2010)(
- Thesis › Doctoral thesis (compilation)
- 2009
-
Mark
Lactoferricin treatment decreases the rate of cell proliferation of a human colon cancer cell line.
(
- Contribution to journal › Article
- 2008
-
Mark
Lactoferricin treatment delays cell cycle progression of a human colon cancer cell line
2008) 20th Meeting of the European Association for Cancer Research In EJC Supplements 6(9). p.150-150(
- Contribution to journal › Published meeting abstract
- 1983
-
Mark
Suppression of Secondary Antibody Response by Intravenous Immunoglobulin in a Patient with Haemophilia B and Antibodies
(
- Contribution to journal › Article